At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
IONIS MAPTRx +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study, Followed by an Open-Label Extension, to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease
In Brief
A Phase 1 clinical trial evaluating IONIS MAPTRx and Placebo for Mild Alzheimer's Disease. Completed, enrolled 46 participants across 13 sites in 6 countries.
Detailed Summary
The purpose of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Alzheimer's Disease
CountriesCanada, Finland, Germany, Netherlands, Sweden, United Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartOct 2017
Primary CompletionMay 2022
TodayJul 2026
First PostedJun 14, 2017
Enrollment StartOct 12, 2017
Primary CompletionMay 12, 2022
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 9.0 years ago
Interventions
IONIS MAPTRxdrug
IONIS MAPTRx injections.
Placeboother
Artificial CSF injections.